  | Business Development [Licensing]
OrphageniX hold the dominant IP portfolio for targeted gene alteration, including five issued patents and eight pending applications. These patents protect all aspects of the of the Company’s products ranging from composition to methods to utilize single stranded oligonucleotides to induce single point alterations in genes.
OrphageniX is actively pursuing partnerships to accelerate the development and commercialization of selected pipeline products. For more information about partnering, please contact us at: info@orphagenix.com |
Home >